UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
UTHR$582.46+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In millions, except share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,553.9 | $1,207.7 |
| Marketable investments | 1,772.6 | 1,786.4 |
| Accounts receivable, no allowance for 2024 and 2023 | 341.8 | 278.9 |
| Inventories, net | 146.7 | 111.8 |
| Other current assets | 185.4 | 166.2 |
| Total current assets | 4,000.4 | 3,551.0 |
| Marketable investments | 1,279.4 | 1,909.8 |
| Goodwill and other intangible assets, net | 112.1 | 114.2 |
| Property, plant, and equipment, net | 1,156.7 | 1,045.4 |
| Deferred tax assets, net | 390.9 | 394.8 |
| Other non-current assets | 183.6 | 151.8 |
| Total assets | $7,123.1 | $7,167.0 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $363.9 | $298.0 |
| Line of credit (current) | 400.0 | 400.0 |
| Share tracking awards plan | 29.4 | 35.4 |
| Other current liabilities | 80.1 | 71.0 |
| Total current liabilities | 873.4 | 804.4 |
| Line of credit (non-current) | — | 300.0 |
| Other non-current liabilities | 148.8 | 77.8 |
| Total liabilities | 1,022.2 | 1,182.2 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued | — | — |
| Common stock, par value $.01, 245,000,000 shares authorized, 74,782,248 and 73,659,761 shares issued, and 44,615,658 and 47,040,545 shares outstanding as of September 30, 2024 and December 31, 2023, respectively | 0.7 | 0.7 |
| Additional paid-in capital | 2,647.2 | 2,549.0 |
| Accumulated other comprehensive income (loss) | 7.4 | (12.8) |
| Treasury stock, 30,166,590 and 26,619,216 shares as of September 30, 2024 and December 31, 2023, respectively | (3,475.3) | (2,579.2) |
| Retained earnings | 6,920.9 | 6,027.1 |
| Total stockholders’ equity | 6,100.9 | 5,984.8 |
| Total liabilities and stockholders’ equity | $7,123.1 | $7,167.0 |
| Quarterly Report | 3 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.